TYBR Health lands $30M to protect tissue after orthopedic surgery
What's the deal? TYBR Health has raised $30 million in a round led by Vensana CapitalDealroom has a profile for this one. Try Dealroom → and Mutual Capital PartnersDealroom has a profile for this one. Try Dealroom →, with participation from Neovate Capital PartnersDealroom has a profile for this one. Try Dealroom → and existing investors. The Houston-based medical technology company will use the funds to expand commercial access to its FDA-cleared B3 GEL® System, broaden product indications, and run clinical studies on tissue protection during orthopedic surgery.
What's the endgame? TYBR builds technology for the healing window after surgery. Its B3 GEL® System is a flowable extracellular matrix hydrogel designed to protect tendons, ligaments, muscles, and surrounding soft tissue as they heal.
Why now? Surgeons have had few tools to influence how tissue recovers in the days and weeks after an operation — a period that shapes scarring, mobility, pain, and returned function. Since launch, the system has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures.
What they're saying: "Surgeons are exceptionally good at the structural repair, but the biology that follows is what determines how it heals," said Tim Keane, co-founder and chief executive officer of TYBR Health. "This financing lets us reach more surgeons and generate the clinical evidence to move that shift forward."
Greg Banker of Vensana Capital and Liz Todia Zambory of Mutual Capital Partners will join the board, alongside independent director Aaron Smith. "TYBR has shown real commercial traction early and built a strong team," Banker said.
The signal: Unlike sheet-based barriers, B3 GEL® conforms to complex anatomy and fits within existing surgical workflows. The round reflects a broader shift across surgical specialties toward weighing the biological conditions repairs need to succeed, not just the mechanical fix.
Read more: PR Newswire
Image credit: TYBR Health
